Skip to main content
SpringerLink
Log in

Chemoimmuntherapie zur neoadjuvanten Behandlung des lokal fortgeschrittenen Non-Small-Cell Lung Cancer (NSCLC)

Histologisches Tumoransprechen ist ein Surrogatparameter für Überleben

Chemoimmunotherapy for neoadjuvant treatment of locally advanced non-small-cell lung cancer (NSCLC)

Histological tumor response is a surrogate parameter for survival

  • Journal Club
  • Published:
Der Pneumologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Swaminath A, Vella ET, Ramchandar K et al (2019) Surgery after chemoradiotherapy in patients with stage III (N2 or N3, excluding T4) non-small-cell lung cancer: a systematic review. Curr Oncol 26(3):e398–404

    Article  CAS  Google Scholar 

  2. Provencio M, Nadal E, Insa A et al (2020) Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 21(11):1413–1422

    Article  CAS  Google Scholar 

  3. Chae YK, Arya A, Iams W et al (2018) Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer 6(1):39. https://doi.org/10.1186/s40425-018-0349-3

    Article  PubMed  PubMed Central  Google Scholar 

  4. Forde PM, Chaft JE, Smith KN et al (2018) Neoadjuvant PD‑1 blockade in resectable lung cancer. N Engl J Med 378(21):1976–1986

    Article  CAS  Google Scholar 

  5. Walles T (2018) Neoadjuvante Therapie des operablen NSCLC mit Immun-Checkpoint-Inhibitoren. Pneumologe 15:349–350

    Article  Google Scholar 

  6. Lücke E, Ganzert C, Föllner S et al (2020) Operabilität und pathologisches Ansprechen des Lungenkarzinoms nach neoadjuvanter Therapie mit Immun-Checkpoint-Inhibitoren. TumorDiagn Ther 41(10):695–701

    Article  Google Scholar 

  7. Shu CA, Gainor JF, Awad MM et al (2020) Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 21(6):786–795

    Article  CAS  Google Scholar 

  8. Hellmann MD, Chaft JE, William WN et al (2014) Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol 15:e42–50

    Article  CAS  Google Scholar 

  9. Sorensen JB, Ravn J, Pilegaard HK et al (2013) Surgery for nsclc stages T1–3N2M0 having preoperative pathologically verified N2 involvement: a  prospective randomized multinational phase iii trial by the nordic thoracic oncology group [abstract 7504]. J Clin Oncol. https://doi.org/10.1200/jco.2013.31.15_suppl.7504

    Article  PubMed  PubMed Central  Google Scholar 

  10. Zhang XN, Huang L (2017) Neoadjuvant chemotherapy followed by surgery versus upfront surgery in non-metastatic non-small cell lung cancer: systematic review and meta-analysis of randomized controlled trials. Oncotarget 8:90327–90337

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Herz- und Thoraxchirurgie, Universitätsklinikum Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Deutschland

    Thorsten Walles FETCS

Authors
  1. Thorsten Walles FETCS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thorsten Walles FETCS.

Ethics declarations

Interessenkonflikt

T. Walles gibt an, dass kein Interessenkonflikt besteht.

Additional information

Redaktion

Jens Schreiber, Magdeburg

Peter Zabel, Lübeck/Borstel

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Walles, T. Chemoimmuntherapie zur neoadjuvanten Behandlung des lokal fortgeschrittenen Non-Small-Cell Lung Cancer (NSCLC). Pneumologe 18, 123–125 (2021). https://doi.org/10.1007/s10405-021-00382-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10405-021-00382-5

Search

Navigation